RhoA/Rho激酶在2型糖尿病大鼠肝脏纤维化中的作用

被引:8
作者
房彩霞 [1 ]
周红 [1 ]
李贵芝 [1 ]
王德峰 [2 ]
王绵 [1 ]
机构
[1] 河北医科大学第二医院内分泌科
[2] 河北工程大学附属医院内分泌科
关键词
糖尿病肝纤维化; Rho激酶; 转化生长因子β1; 结缔组织生长因子; 法舒地尔;
D O I
10.16352/j.issn.1001-6325.2014.03.015
中图分类号
R587.1 [糖尿病]; R575.2 [肝硬变];
学科分类号
100201 [内科学];
摘要
目的阐明RhoA/Rho激酶在糖尿病大鼠肝纤维化中的作用。方法通过高脂饮食和小剂量链脲佐菌素(STZ,30 mg/kg)腹腔注射建立2型糖尿病大鼠模型。实验分为对照组、糖尿病组和法舒地尔干预组(法舒地尔10 mg/(kg·d),分两次腹腔注射)24周末。测定血糖、血脂、谷草转氨酶和谷丙转氨酶;Masson染色和羟脯氨酸测定评估肝胶原沉积;RT-PCR测定转化生长因子β1(TGF-β1)和结缔组织生长因子(CTGF)mRNA表达;免疫组化测定TGF-β1蛋白表达;Western blot测定肝组织肌球蛋白磷酸酯酶靶点亚单位1磷酸化(p-MYPT1)水平。结果与对照组比较,糖尿病组大鼠血糖、血脂和转氨酶显著增高,肝组织大量胶原沉积,p-MYPT1水平、TGF-β1与CTGF mRNA表达显著上调(P<0.01)。与糖尿病组比较,法舒地尔干预组大鼠转氨酶降低,肝胶原沉积明显减轻,p-MYPT1水平、TGF-β1与CTGF mRNA表达显著下降(P<0.01)。结论高血糖激活了肝组织RhoA/Rho激酶,通过调控TGF-β1/CTGF表达,在糖尿病肝纤维化中起着重要作用。
引用
收藏
页码:332 / 338
页数:7
相关论文
共 9 条
[1]
Rho Kinase Inhibitors: Potential Treatments for Diabetes and Diabetic Complications [J].
Zhou, Hong ;
Li, Yong-jun .
CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (20) :2964-2973
[2]
Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes [J].
Qiang, Guifen ;
Zhang, Li ;
Yang, Xiuying ;
Xuan, Qi ;
Shi, Lili ;
Zhang, Hengai ;
Chen, Bainian ;
Li, Xiaoxiu ;
Zu, Mian ;
Zhou, Dan ;
Guo, Jing ;
Yang, Haiguang ;
Du, Guanhua .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2012, 685 (1-3) :156-164
[3]
Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: The Hidden Epidemic [J].
Ismail, Mona H. .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2011, 341 (06) :485-492
[4]
Rho-Kinase Inhibitor Attenuates Cholestasis-Induced CXC Chemokine Formation, Leukocyte Recruitment, and Hepatocellular Damage in the Liver [J].
Laschke, Matthias W. ;
Dold, Stefan ;
Jeppsson, Bengt ;
Schilling, Martin K. ;
Menger, Michael D. ;
Thorlacius, Henrik .
JOURNAL OF SURGICAL RESEARCH, 2010, 159 (02) :666-673
[5]
TGF‐β–induced fibrosis and SMAD signaling: oligo decoys as natural therapeutics for inhibition of tissue fibrosis and scarring.[J].Kenneth R.Cutroneo.Wound Repair and Regeneration.2007,
[6]
Therapeutic strategies against TGF-β signaling pathway in hepatic fibrosis [J].
Liu, XJ ;
Hu, H ;
Yin, JQ .
LIVER INTERNATIONAL, 2006, 26 (01) :8-22
[7]
Connective tissue growth factor (CTGF/CCN2) in hepatic fibrosis [J].
Rachfal, AW ;
Brigstock, DR .
HEPATOLOGY RESEARCH, 2003, 26 (01) :1-9
[8]
High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: A potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis [J].
Paradis, V ;
Perlemuter, G ;
Bonvoust, F ;
Dargere, D ;
Parfait, B ;
Vidaud, M ;
Conti, M ;
Huet, S ;
Ba, N ;
Buffet, C .
HEPATOLOGY, 2001, 34 (04) :738-744
[9]
Inhibitory effect of Y-27632, a ROCK inhibitor, on progression of rat liver fibrosis in association with inactivation of hepatic stellate cells [J].
Murata, T ;
Arii, S ;
Nakamura, T ;
Mori, A ;
Kaido, T ;
Furuyama, H ;
Furumoto, K ;
Nakao, T ;
Isobe, N ;
Imamura, M .
JOURNAL OF HEPATOLOGY, 2001, 35 (04) :474-481